Claims for Patent: 6,436,706

Summary for Patent: 6,436,706

Title:	Antisense inhibitor of RECQL4 expression
Abstract:	Antisense compounds, compositions and methods are provided for modulating the expression of RECQL4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL4. Methods of using these compounds for modulation of RECQL4 expression and for treatment of diseases associated with expression of RECQL4 are provided.
Inventor(s):	Ward; Donna T. (Murrieta, CA), Watt; Andrew T. (Vista, CA)
Assignee:	ISIS Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	09/792,594
Patent Claims:	1. A compound 8 to 50 nucleobases in length targeted to nucleobases 345 through 397, nucleobases 467 through 486, nucleobases 498 through 517, nucleobases 756 through 775, nucleobases 786 through 805, nucleobases 1044 through 1063, nucleobases 1103 through 1148, nucleobases 1223 through 1242, nucleobases 1269 through 1288, nucleobases 1475 through 1494, nucleobases 1612 through 1645, nucleobases 1696 through 1715, nucleobases 1814 through 1833, nucleobases 1869 through 1908, nucleobases 1939 through 1977, nucleobases 2019 through 2038, nucleobases 2109 through 2128, nucleobases 2214 through 2243, nucleobases 2278 through 2297, nucleobases 2307 through 2326, nucleobases 2387 through 2406, nucleobases 2418 through 2437, nucleobases 2478 through 2497, nucleobases 2522 through 2541, nucleobases 2545 through 2576, nucleobases 2675 through 2741, nucleobases 2746 through 2765, nucleobases 2772 through 2791, nucleobases 2795 through 2814, nucleobases 2949 through 3008, nucleobases 3020 through 3039, nucleobases 3046 through 3065, nucleobases 3091 through 3110, nucleobases 3117 through 3136, nucleobases 3139 through 3148, nucleobases 3163 through 3182, nucleobases 3227 through 3246, nucleobases 3385 through 3409, nucleobases 3425 through 3444, or nucleobases 3464 through 3492 of a coding region or nucleobases 3607 through 3626 of a stop codon region of a nucleic acid molecule encoding RECQL4 of SEQ ID NO: 3, nucleobases 580 through 599 of an intron 4 region, nucleobases 1055 through 1074 of an intron 5 region, nucleobases 2108 through 2127 of an intron:exon junction region, nucleobases 2191 through 2210 of an intron 7 region, nucleobases 3673 through 3692 of an exon 11 region, nucleobases 3871 through 3990 of an intron 13 region, nucleobases 4214 through 4223 or nucleobases 4248 through 4267 of an intron 14 region, or nucleobases 5176 through 5195 of an intron 17 region of a nucleic acid molecule encoding RECQL4 of SEQ ID NO: 10, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of RECQ4. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of RECQL4 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of RECQL4 is inhibited. 14. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 12, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33, 34, 37, 38, 40, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, or 86 which inhibits the expression of RECQL4. 15. The compound of claim 14 which is an antisense oligonucleotide. 16. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A composition comprising the compound of claim 14 and a pharmaceutically acceptable carrier or diluent. 24. The composition of claim 23 further comprising a colloidal dispersion system. 25. The composition of claim 23 wherein the compound is an antisense oligonucleotide. 26. A method of inhibiting the expression of RECQL4 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 14 so that expression of RECQL4 is inhibited. 27. A compound consisting of SEQ ID NO: 13, 14, 21, 36, 41, 47 or 88.

Details for Patent 6,436,706

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26